June 29, 2026 a 07:46 am
MRK: Dividend Analysis - Merck & Co., Inc.
Merck & Co., Inc., sustains a robust dividend profile characterized by a stable history and promising growth prospects. With a market capitalization of $317 billion, its long tenure in dividend distribution underscores a commitment to returning capital to shareholders. Analyzing the dividend yield and growth potential, Merck stands as a compelling choice for dividend-focused investors eager to capitalize on stable, long-term income streams.
📊 Overview
Merck & Co., Inc. showcases a well-rounded dividend profile within its sector. The company's commitment to consistent payouts is reflected in its impressive dividend history.
| Key Metric | Value |
|---|---|
| Sector | Pharmaceuticals |
| Dividend yield | 2.92% |
| Current dividend per share | 3.27 USD |
| Dividend history | 57 years |
| Last cut or suspension | None |
📈 Dividend History
Merck & Co., Inc.'s dividend history indicates its solid commitment to rewarding shareholders. A stable and growing dividend is a signal of confidence in a company's financial health and future prospects.
| Year | Dividend per Share (USD) |
|---|---|
| 2026 | 1.70 |
| 2025 | 3.28 |
| 2024 | 3.12 |
| 2023 | 2.96 |
| 2022 | 2.80 |
📈 Dividend Growth
Analyzing the dividend growth of Merck & Co., Inc. provides insights into its financial growth trajectory. Consistent growth in dividends signals robust company earnings and robust fundamentals.
| Time | Growth |
|---|---|
| 3 years | 5.42% |
| 5 years | 6.75% |
The average dividend growth is 6.75% over 5 years. This shows moderate but steady dividend growth.
📊 Payout Ratio
The payout ratio is crucial in assessing Merck & Co., Inc.'s dividend sustainability. A high payout ratio may limit future dividend increases.
| Key figure ratio | Value |
|---|---|
| EPS-based | 90.41% |
| Free cash flow-based | 57.18% |
The EPS-based payout ratio of 90.41% is on the higher side, suggesting limited room for further dividend increase using earnings alone. However, the free cash flow-based ratio of 57.18% is more sustainable.
📊 Cashflow & Capital Efficiency
A solid cash flow and capital efficiency are critical to maintaining Merck & Co., Inc.'s ability to pay and grow dividends.
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Free Cash Flow Yield | 3.22% | 7.18% | 4.69% |
| Earnings Yield | 0.13% | 6.80% | 6.93% |
| CAPEX to Operating Cash Flow | 29.70% | 15.71% | 24.96% |
| Stock-based Compensation to Revenue | 1.07% | 1.19% | 0.00% |
| Free Cash Flow / Operating Cash Flow Ratio | 70.30% | 84.29% | 75.04% |
Merck & Co., Inc.'s cashflow metrics indicate a solid foundation for sustaining and potentially growing dividends. Consistent operating cash flow and limited CAPEX facilitate continued shareholder rewards.
📊 Balance Sheet & Leverage Analysis
Merck & Co., Inc.'s balance sheet strength and leverage metrics are fundamental to understanding its financial health and risk management.
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Debt-to-Equity | 96.51% | 82.63% | 96.06% |
| Debt-to-Assets | 34.00% | 32.68% | 36.92% |
| Debt-to-Capital | 49.11% | 45.25% | 48.99% |
| Net Debt to EBITDA | 4.26 | 0.97 | 1.27 |
| Current Ratio | 1.25 | 1.36 | 1.54 |
| Quick Ratio | 1.00 | 1.15 | 1.30 |
| Financial Leverage | 2.84 | 2.53 | 2.60 |
**Merck & Co., Inc.** demonstrates moderate leverage with stable debt ratios. This implies manageable financial risk and a balanced approach to finance its operations and growth.
📊 Fundamental Strength & Profitability
Merck & Co., Inc.'s fundamental strength and profitability indicators are key measures of its financial health and operational efficiency.
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Return on Equity | 0.97% | 36.96% | 34.70% |
| Return on Assets | 0.34% | 14.62% | 13.34% |
| Margins: Net | 0.61% | 26.68% | 28.12% |
| Margins: EBIT | 5.05% | 33.05% | 34.54% |
| Margins: EBITDA | 11.49% | 40.06% | 43.53% |
| Margins: Gross | 73.17% | 76.32% | 71.98% |
| Research & Development to Revenue | 50.79% | 27.95% | 19.27% |
Merck & Co., Inc.'s profitability and return metrics suggest strong operational efficiency, which is crucial for sustaining competitiveness and ensuring future growth prospects.
📉 Price Development
📊 Dividend Scoring System
| Category | Score | Score Bar |
|---|---|---|
| Dividend yield | 4 | |
| Dividend Stability | 5 | |
| Dividend growth | 4 | |
| Payout ratio | 3 | |
| Financial stability | 4 | |
| Dividend continuity | 5 | |
| Cashflow Coverage | 4 | |
| Balance Sheet Quality | 4 |
Total Score: 33/40
🏆 Rating
Merck & Co., Inc. presents a strong investment opportunity with its consistent dividend payouts, moderate growth, and excellent financial resilience. It is a highly recommended stock for income-focused investors seeking long-term value and stability.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years